Xeris Biopharma Holdings Inc
XERS
$1.76
Closing
▼-1.12%
1D
▼-25.11%
YTD
Market cap
$247.20M
52 week high
$3.26
52 week low
$1.47
Volume
314,486
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$247.20M
Analysts' Rating
BUY
Price Target (Mean)
4.6
Total Analysts
5
P/E
Operating Margin
-16.04%
Beta
1.66
Revenue Growth (Annual)
122.32%
52 week high
$3.26
52 week low
$1.47
Div. Yield
%
EPS Annual Growth
-35.71
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on improving patients’ lives by developing and commercializing products across a range of therapies. The Company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), and Levothyroxine (XP-8121). XP-8121, is an early-stage program designed to address maintenance therapy in patients with congenital or acquired hypothyroidism who require continuous thyroid hormone replacement.
